임상 한눈에 보기

• 1건의 ClinicalTrials.gov 임상 기록
• 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
• 모집 중 2건 · 완료/종료 0건
• Phase: PHASE1, PHASE2 · PHASE2
• Status: RECRUITING · UNKNOWN
• 주요 endpoint: Phase 1: safety and tolerability of increasing dose levels of orally administered NEO212 alone in patients with Astrocytoma IDH-mutant · Glioblastoma IDH-wildtype or patients with select solid tumors with uncontrolled metastases to the brain · Phase 1: Identify the maximum tolerated dose (MTD) of NEO212 · Phase 1: Determine the recommended Phase 2 dose (RP2D) of NEO212 · Phase 2a: Assess the safety and tolerability of orally administered NEO212 in combination with select SOC regimens following a standard 3+3 design in patients with select solid tumors with uncontrolled metastases to the brain
• 등록 대상자(표본 합산): 약 264명

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.